Friday, May 25, 2018

Illumina Spinout Grail Gets $300M More For Cancer Detection Testing

Grail, the spinout of San Diego-based life sciences equipment maker Illumina, has raised $300M more in funding, the company said this week. The startup is developing blood testing technology which uses DNA analysis to help in early detection of cancer. The funding came from Ally Bridge Group, Hillhouse Capital, 6 Dimensions Capital, Blue Pool Capital, China Merchant Securities International, CRF Investment, HuangPu River Capital, ICBC International, Sequoia Capital China and WuXi NextCODE. The startup, led by CEO Jennifer Cook, is based in Menlo Park, in the Bay Area. More information »